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Muntingia calabura L. (family Elaeocarpaceae) has been traditionally used to relieve various pain-related ailments. The present
study aimed to determine the antinociceptive activity of methanol extract of M. calabura leaves (MEMC) and to elucidate
the possible mechanism of antinociception involved. The in vivo chemicals (acetic acid-induced abdominal constriction and
formalin-, capsaicin-, glutamate-, serotonin-induced paw licking test) and thermal (hot plate test) models of nociception were
used to evaluate the extract antinociceptive activity. The extract (100, 250, and 500mg/kg) was administered orally 60min prior to
subjection to the respective test. The results obtained demonstrated that MEMC produced signiﬁcant (P<0.05) antinociceptive
response in all the chemical- and thermal-induced nociception models, which was reversed after pretreatment with 5mg/kg
naloxone, a non-selective opioid antagonist. Furthermore, pretreatment with L-arginine (a nitric oxide (NO) donor), N
G-nitro-
L-arginine methyl esters (L-NAME; an inhibitor of NO synthase (NOS)), methylene blue (MB; an inhibitor of cyclic-guanosine
monophosphate (cGMP) pathway), or their combination also caused signiﬁcant (P<0.05) change in the intensity of the MEMC
antinociception. In conclusion, the MEMC antinociceptive activity involves activation of the peripheral and central mechanisms,
and modulation via, partly, the opioid receptors and NO/cGMP pathway.
1.Introduction
Muntingia calabura L. (family Elaeocarpaceae), the sole
species in the genus Muntingia, is a ﬂowering plant native
to southern Mexico, the Caribbean, Central America, and
western South America. The tree grows very easily and
is widespread, and, in Malaysia, it is popularly known as
“Kerukup Siam.” Despite less attention given to its medicinal
values in the Malay folklore medicine, M. calabura has been
traditionally used by the Peruvian to treat various ailments
[1, 2]. According to the Peruvian folklore, its leaves can
either be boiled or steeped in water to provide relief from
gastriculceror to reduceswelling ofthe prostate gland, while
the strips of its bark are boiled and washed to reduce the
swellinginthelowerextremities[3].Theleaves,inparticular,
have been used to treat pain associated with gastric ulcers,
headache,andcoldortoattenuatetheprostateglandswelling
[1, 2, 4]. Scientiﬁcally, the leaves of M. calabura have been
reported to possess antitumour [5, 6], antinociceptive [3,
7, 8], anti-inﬂammatory and antipyretic [3, 9], antibacterial
[10], and antiproliferative and antioxidant [11] activities of
M. calabura leaves. Phytochemical screening of the leaves
demonstrated the presence of ﬂavonoids, saponins, tannins,
triterpenes, and steroids, but no alkaloids [8], while the
phytochemical analysis of methanol extract of M. calabura
leaves (MEMC) revealed only the presence of ﬂavonoids,
saponins, and tannins [11]. The previous antinociceptive,
anti-inﬂammatory, and antipyretic activity of M. calabura
leaves, in particular, has been investigated using the aqueous
extract of the leaves. Thus, the present study aims to report2 Evidence-Based Complementary and Alternative Medicine
for the ﬁrst time the antinociceptive proﬁle of MEMC and
the possible mechanism of actions involved.
2.Methodology
2.1. Plant Collection. The leaves of M. calabura,c o l l e c t e d
from its natural habitat in Shah Alam, Selangor, Malaysia,
were reidentiﬁed by Mr. Shamsul Khamis from the Institute
of Bioscience (IBS), Universiti Putra Malaysia (UPM), Ser-
dang, Selangor, Malaysia. A voucher specimen (SK 1095/05)
has been deposited at the Herbarium of the Laboratory of
Natural Products, IBS, UPM, Serdang, Selangor, Malaysia.
2.2. Preparation of MEMC. This procedure was carried out
as described in detail by Zakaria et al. [11]. Brieﬂy, 500g
of matured leaves that have been air-dried for 1-2 weeks
at room temperature (27 ± 2◦C) and grinded into powder
were soaked in methanol in the ratio of 1:20 (w/v) for 72
hours. After that, the supernatant was ﬁltered using steel
ﬁlter, cotton, and Whatman no. 1 ﬁlter paper. The residue
was subjected to the same procedures for another two times.
The supernatant collected from each extraction was pooled
together and then subjected to evaporation process using a
rotary evaporator at 40◦Cu n d e rr e d u c e dp r e s s u r e .
2.3. Drugs and Chemicals. The following reagents and drugs
wereused:methanol(FischerScientiﬁc,UK),DMSO,forma-
lin, acetic acid, morphine, acetylsalicylic acid (ASA), nalox-
one, capsaicin, glutamate, L-arginine, NG-nitro-L-arginine
methyl esters (L-NAME), and methylene blue (MB) (Sigma,
USA). The drugs were prepared by dissolving them into
distilled water. The MEMC was dissolved in vehicle (10%
DMSO) just before used. All solutions were administered in
the volume of 10mL/kg.
2.4. Animals. Male Sprague Dawley rats (180–200g; 8–
10 weeks old) and male ICR mice (25–30g; 5–7 weeks
old) obtained from the Veterinary Animal Unit, Faculty
of Veterinary Medicine, Universiti Putra Malaysia (UPM),
Malaysia, and kept under room temperature (27 ± 2◦C;
70–80% humidity; 12h light/darkness cycle) in the Animal
Holding Unit (UPM), were supplied with food and water
ad libitum up to the beginning of the experiments. The
rats were, at all times, handled in accordance with current
UPM guidelines for the care of laboratory animals and the
ethical guidelines for investigations of experimental pain
in conscious animals [12]. All experiments (n = 6) were
conducted between 09.30 and 18.30h to minimize the eﬀects
of environmental changes.
2.5. Antinociceptive Activity
2.5.1. Acetic-Acid-Induced Abdominal Constriction Test. The
acetic-acid-induced abdominal constriction test was carried
out according to the method described by Zakaria et al.
[3] with slight modiﬁcation. The mice (n = 6) were
pretreated with 10% DMSO (negative control), 100mg/kg
ASA(positivecontrol),orMEMC(100,250,and500mg/kg).
Sixty minutes after the respective test solution administra-
tion, the mice were injected via intraperitoneal (i.p.) route
with phlogistic agent (0.6% acetic acid). The animals were
immediately placed individually into glass cage, and 5min
were allowed to elapse. The abdominal constriction resulting
from the injection of acetic acid consists of a contraction
of the abdominal together with a stretching of at least
one hind limb. The number of abdominal constrictions
produced in these animals was counted cumulatively for
25min. Antinociceptive activity, indicated by the reduction
in the mean of the number of abdominal constrictions in the
test groups compared to the control group, was calculated
as the percentage inhibition of abdominal constrictions
(percentage of inhibitory level) using the following formula:
(mean of (control-test group)/control group × 100%).
2.5.2. Hot Plate Test. The hot plate test was carried out
according to the method described by Wilson et al. [13]w i t h
some modiﬁcations. The temperature of the metal surface
(Ugo Basile 7280) was set at 50 ± 0.2 ◦C. The mice (n = 6)
werepretreatedwith10%DMSO(negativecontrol),5mg/kg
morphine (positive control), or MEMC (100, 250, and
500mg/kg). Sixty minutes after the respective test solution
administration, the mice were placed on the heated metal
surface and the latency to a discomfort reaction (licking
paws or jumping) was recorded. The cut-oﬀ time of 20s was
chosen to avoid tissue injury. Latency was record before and
60, 90, 120, 150, 180, 210min following oral administration
of the treatments. The prolongation of the latency times
compared with the values of the controls was used for
statistical comparison.
2.5.3. Formalin-Induced Paw Licking Test. The formalin test
w a sc a r r i e do u ta sd e s c r i b e db yZ a k a r i ae ta l .[ 3]b u tw i t h
slight modiﬁcations. Pain was induced by injecting 50μLo f
5% formalin in the subplantar region of the right hind paw.
Rats(n = 6)wereorallyadministeredwith10%DMSO(neg-
ative control), 100mg/kg ASA, 5mg/kg morphine (positive
control), or MEMC (100, 250, and 500mg/kg) 60min prior
to the formalin injection. Immediately after the phlogistic
agent administration, the rats were individually placed in
a transparent glass cage observation chamber. The amount
of time that the animal spent licking the injected paw,
considered as an indicator of pain, was recorded for duration
of 30min in two phases, known as the early (0–5min) and
late (15–30min) phases.
2.5.4. Capsaicin-Induced Paw Licking Test. To investigate the
role of vanilloid receptors in the modulation of MEMC
antinociceptive action, the procedure described by Goncales
et al. [14] was adopted with slight modiﬁcations. Rats were
pretreated orally with 10% DMSO or MEMC (100, 250, and
500mg/kg) 60min before capsaicin injection (1.6ug/paw,
20uL) into the intraplantar (i.pl.) region of the rat’s right
hind paw. Immediately after the phlogistic agent adminis-
tration, the rats were individually placed in a transparent
glass cage observation chamber and observed individually
for 5min after the capsaicin injection. The amount of timeEvidence-Based Complementary and Alternative Medicine 3
the animals spent licking the injected paw was recorded
with a chronometer and was considered as an indication of
nociception.
2.5.5. Glutamate-Induced Paw Licking Test. To study the
role of glutamatergic system in the modulation of MEMC
antinociceptive action, the procedure described by Beirith
et al. [15] with slight modiﬁcations were performed. Rats
were pretreated orally with 10% DMSO or MEMC (100,
250, and 500mg/kg) 60min prior to glutamate injection.
Av o l u m eo f2 0 μL of glutamate (10umol/paw, in normal
saline) was injected via i.pl. route in the right hind paw of
rats. Immediately after the phlogistic agent administration,
the rats were individually placed in a transparent glass cage
observation chamber and observed individually from 0 to
15min after the glutamate injection. The amount of time the
animals spent licking or biting the injected paw was recorded
with a chronometer and was considered as an indication of
nociception.
2.5.6. Involvement of Opioid Receptor. To determine the role
of opioid receptors in the modulation of MEMC antinoci-
ceptive activity, a separate procedure described by Zakaria
et al. [16] was adopted with slight modiﬁcations. Two
groups of animals (n = 6) were pretreated (i.p.) with a
nonselective opioid antagonist, naloxone (5mg/kg; i.p) for
15min followed by the oral administration of the most
eﬀective MEMC dose (500mg/kg). Sixty minutes later, the
animals are subjected to the acetic-acid-induced abdominal
writhing test and the formalin test.
2.5.7. Involvement of Nitric Oxide/Cyclic-Guanosine Mon-
ophosphate Pathway. To determine the role of nitric oxide/
cyclic-guanosine monophosphate (NO/cGMP) pathway in
the modulation of MEMC antinociceptive activity, the
method described by Zakaria et al. [16]w a sa d o p t e dw i t h
slight modiﬁcations. Mice (n = 6) were pretreated with
20mg/kg L-arginine, L-NAME, MB, or their respective
combination (L-arginine with L-NAME or L-arginine with
MB) followed 5min later by pretreatment with 10% DMSO
or MEMC (500mg/kg), respectively. Sixty minutes after the
administration of test solutions, the mice were injected (i.p.)
with 0.6% acetic acid.
2.6. Statistical Analysis. The results are presented as Mean ±
standard error of mean (SEM). The one-way ANOVA test
with Dunnett post hoc test was used to analyze and compare
the data, with P<0.05 as the limit of signiﬁcance.
3. Result
3.1. Acetic-Acid-Induced Abdominal Constriction Test. The
MEMC (100, 250, and 500mg/kg, p.o.) demonstrated a
signiﬁcant (P<0.001) and dose-dependent antinociceptive
activity in the acetic-acid-induced abdominal constriction
test (Figure 1) with the percentage of analgesia ranging
between 30 to 67%. The 250mg/kg MEMC produced an
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Figure 1: Eﬀect of MEMC in acetic-acid-induced abdominal
constriction test in mice. Acetic acid administered intraperitoneally
60min before pretreated with vehicle (control), acetylsalicylic acid
(ASA), or MEMC (100, 250, and 500mg/kg). All treatments
administered via oral route. The asterisks denote the signiﬁcance
levels as compared to control, ∗∗∗P<0.001 by one-way ANOVA
followed by Dunnett’s post hoc test. ∗∗∗Data diﬀered signiﬁcantly
(P<0.001) when compared to the 10% DMSO-treated group.
antinociceptive activity that was comparable to the standard
control (100mg/kg ASA).
3.2. Hot Plate Test. Table 1 shows the antinociceptive proﬁle
of orally administered MEMC assessed using the hot plate
test. MEMC, only at the dose of 500mg/kg, exhibited
signiﬁcant (P<0.001) ability to prolong the latency of
response to discomfort against thermal-induced nociception
throughout the whole experiment. Overall, 5mg/kg mor-
phine demonstrated the most eﬀectiveeﬀectwhencompared
to the MEMC at all doses used.
3.3. Formalin-Induced Paw Licking Test. Overall, the MEMC
demonstrated a signiﬁcant (P<0.05) antinociceptive
activity in both phases of the formalin-induced paw licking
test (Figures 2(a) and 2(b)). The extract exhibited a dose-
dependent eﬀect in the early, but not late, phase with
antinociceptiveactivityseenonlywiththe250and500mg/kg
MEMC, whereas, in the late phase, all doses of MEMC
exerted signiﬁcant (P<0.05) antinociceptive activity in a
dose-independent manner and almost equivalent strength.
As a comparison to MEMC, 5mg/kg morphine also atten-
uated both phases of nociception while 100mg/kg ASA only
reducednociceptioninthelatephase.Overall,morphinewas
eﬀective than ASA and MEMC in both phases of formalin
t e s t ,w h i l eA S Aw a se ﬀective than MEMC in the late phase of
the same test.
3.4. Capsaicin-Induced Paw Licking Test. The antinociceptive
proﬁle of MEMC assessed using capsaicin-induced paw4 Evidence-Based Complementary and Alternative Medicine
Table 1: Eﬀect of MEMC on the hot plate test in mice.
Treatment
Dose
(mg/kg)
Latency of discomfort(s) at respective time interval (min)
0min 60min 90min 120min 150min 180min 210min
10% DMSO 6.97 ±0.22 6.90 ±0.23 6.15 ±0.15 6.72 ±0.16 6.92 ±0.23 6.88 ±0.29 6.35 ±0.17
Morphine 5 5.77 ±0.15 17.37 ± 1.03a 18.25 ±0.74a 16.52 ±1.22a 13.67 ±1.43a 11.22 ±1.11a 10.48 ±0.58a
MEMC
100 6.50 ±0.13 7.12 ±0.17 6.40 ±0.32 6.58 ±0.32 6.87 ±0.24 6.97 ±0.50 6.75 ±0.26
250 5.68 ±0.14 6.93 ±0.16 7.50 ±0.48a 7.75 ±0.36 7.68 ±0.37 7.43 ±0.24 7.72 ±0.40a
500 6.95 ±0.18 10.65±0.47ab 10.22±0.42ab 9.80 ±0.95ab 9.48 ±0.38ab 9.88 ± 0.18ab 9.28 ±0.32a
Naloxone 5 6.38 ±0.27 6.43 ±0.41 5.98 ±0.46 6.10 ±0.21 5.93 ±0.68 6.13 ±0.58 5.67 ±0.54
Naloxone + MEMC 5 + 500 6.02 ±0.27 5.75 ±0.23c 5.55 ±0.25c 5.65 ±0.47c 5.75 ±0.64c 5.97 ±0.61c 5.75 ±0.81c
aData diﬀered signiﬁcantly (P<0.05) when compared against the control group.
bData diﬀered signiﬁcantly (P<0.05) when compared against the 5mg/kg morphine-treated group.
cData diﬀered signiﬁcantly (P<0.05) when compared against the 500mg/kg MEMC-treated group.
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Figure 2: Eﬀect of MEMC in formalin-induced paw licking test. Graph A shows early phase activity, while graph B shows the late phase
analgesic eﬀect. Each column represents the mean ± SEM of 6 rats. The rats were pretreated with vehicle (10% DMSO), MEMC (100, 250,
and 500mg/kg, p.o.), acetylsalicylic acid (ASA, p.o.), or morphine (5mg/kg, p.o.), 60min before i.pl injection of formalin. The asterisks
denote the signiﬁcance levels as compared to control, ∗∗∗P<0.001 by one-way ANOVA followed by Dunnett’s post hoc test. ∗∗∗Data
diﬀered signiﬁcantly (P<0.05) when compared to the 10% DMSO-treated group.
licking test is shown in Figure 3. All doses of MEMC dem-
onstrated a dose-dependent inhibition of capsaicin-induced
nociception with percentage of analgesia ranging between 20
and 62%.
3.5. Glutamate-Induced Paw Licking Test. Figure 4 shows
the antinociceptive proﬁle of MEMC against glutamate-
induced paw licking test. All doses of MEMC also exerted
a dose-dependent inhibition with the percentage of analgesia
ranging from 35 to 72%.
3.6. Involvement of Opioid Receptors. The eﬀect of non-
selective opioid antagonist (5mg/kg naloxone) on MEMC
antinociceptive activity assessed using the abdominal
constriction test, hot plate test, and formalin-induced
paw licking test are shown in Figure 1, Table 1,a n dEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of MEMC on capsaicin-induced paw licking test
in rats. Each column represents the mean ± SEM of 6 rats. The
rats were pretreated with vehicle (control, 10% DMSO) or MEMC
(100, 250, and 500mg/kg, p.o.) 60min before injection of capsaicin
(1.6ug/paw, 20μL, i.pl.). The asterisks denote the signiﬁcance levels
as compared to control, ∗∗∗P<0.001 by one-way ANOVA followed
by Dunnett’s post hoc test.
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Figure 4: Eﬀect of MEMC on glutamate-induced paw licking test
in rats. Each column represents the mean ± SEM of 6 rats. The
rats were pretreated with vehicle (control, 10% DMSO) or MEMC
(100,250,and500mg/kg,p.o.)60minbeforeinjectionofglutamate
(10umol/paw, 20μL, i.pl.). The asterisks denote the signiﬁcance
levels as compared to control, ∗∗∗P<0.001 by one-way ANOVA
followed by Dunnett’s post hoc test.
Figures 2(a) and 2(b), respectively. Interestingly, the 500
mg/kg MEMC antinociceptive activity was signiﬁcantly
(P<0.05) inhibited in all tests. Moreover, naloxone reversed
the extract antinociception in both phases of the latter test.
3.7. Involvement of NO/cGMP Pathway. Figure 5(a) shows
the eﬀect of L-arginine, L-NAME, or their combination
on 500mg/kg antinociception assessed using the abdominal
constriction test. L-arginine alone did not aﬀect the acetic
acid-induced nociception but signiﬁcantly (P<0.05) re-
versed the MEMC antinociceptive activity. On the other
hand, L-NAME alone exerted signiﬁcant (P<0.05) anti-
nociceptive activity and maintained the MEMC-induced
antinociception as seen when the extract was given alone. L-
arginine was also found to completely reverse the L-NAME-
induced antinociception but when these compounds were
combined and given together with the MEMC, the extract
antinociceptive activity was maintained despite signiﬁcant
(P<0.05) reduction in the percentage of analgesia recorded.
In additional study, MB alone exhibited signiﬁcant (P<
0.001) antinociceptive activity and when given together
with 500mg/kg MEMC maintained the extract antinoci-
ceptive activity as seen when the extract was given alone
(Figure 5(b)). Furthermore, L-arginine failed to reverse MB
antinociceptive activity, whereas their combination also
failed to inhibit the extract antinociceptive activity.
4. Discussion
The present study reported for the ﬁrst time the antinoci-
ceptive potential of MEMC after an oral administration
when assessed using the chemicals (acetic acid and formalin)
and thermal stimuli models of nociception. The extract
exhibited antinociceptive activity in both the chemicals (i.e.,
abdominal constriction test) and thermal (i.e., hot plate
test) nociception models tested indicating that the extract
possessed peripheral and central antinociceptive mecha-
nisms, which is the characteristic of opioid analgesics (i.e.,
morphine).Theinvolvementofbothlevelsofantinociceptive
mechanisms was further proven by the ability of MEMC
to reverse the early and late phases of formalin test, which
is also the characteristic of morphine. Other than that,
the MEMC antinociception was demonstrated to involve
modulation via the opioid receptors, and NO/cGMP path-
way and inhibition of the vanilloid receptors and glutamate
pathways. Interestingly, the involvement of opioid receptors
in MEMC antinociception is postulated to take place at
the peripheral and central levels as indicated by the ability
of naloxone, a nonselective opioid antagonist, to attenuate
the antinociceptive activity of MEMC in the abdominal
constriction test and both phases of the formalin test.
The acetic-acid-induced abdominal constriction test,
described as a typical model for inﬂammatory pain, has
long been widely used as a tool to screen for analgesic or
anti-inﬂammatory properties of new agents [17, 18] and,
in most cases, used as a model to study the peripheral
antinociceptive eﬀect of extracts/compounds. This model
of nociception is suggested to represent the stimulation of
peripheralmechanismsincetheadministrationofphlogogen
lead to an increase in the levels of cyclooxygenase (COX) and
lipooxygenase (LOX) [19] and indirectly leads to the release
of endogenous nociceptive mediators (e.g., prostanoids of
the PGE2 and PGF2α types, serotonin, histamine, cytokines,
and eicosanoids) as well as other LOX products in peritoneal
ﬂuidsthatcaninducevariousperipheralnociceptiveneurons
sensitive to NSAIDs within the peritoneal cavity [17, 20–22].
Prolongirritationoftheperitonealcavityhasbeenassociated
with increase in the PGEs levels in the peritoneal ﬂuid, which
enhances capillary permeability [23, 24] and the release of
glutamate and substance P from peripheral aﬀerent ﬁber ter-
minals [25]. Based on the above-mentioned fact, the ability6 Evidence-Based Complementary and Alternative Medicine
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Figure 5: (a) Eﬀects of L-arginine, L-NAME, and their combination on MEMC antinociception as assessed by acetic-acid-induced
abdominal constriction test. The asterisks denote the signiﬁcance levels as compared to control, ∗∗∗P<0.001 by one-way ANOVA followed
by Dunnett’s post hoc test. (b) Eﬀects of L-arginine, methyline blue, and their combination on MEMC antinociception as assessed by acetic-
acid-induced abdominal constriction test. The asterisks denote the signiﬁcance levels as compared to control, ∗∗∗P<0.001 by one-way
ANOVA followed by Dunnett’s post hoc test. ∗∗∗P<0.001 by one-way ANOVA followed by Dunnett’s post hoc test.
of MEMC to attenuate the acetic-acid-induced abdominal
constriction test suggests that the extract’s antinociceptive
mechanism involves, in part, its ability to inhibit COX
and LOX in the peripheral tissues leading to decrease in
PGEs synthesis and impediment of the pain transduction
in primary aﬀerent nociceptor. Interestingly, the abdominal
constriction test is considered to be a very sensitive noci-
ceptive model since it can detect antinociceptive eﬀect of
compounds/dose levels even at the lowest dosages that might
not be eﬀective in other tests (i.e., hot plate or tail-ﬂick
test) due to direct interaction of the extracts/compounds
with the various peripheral receptors within the peritoneal
cavity [26, 27]. However, this test also has been regarded
as a nonspeciﬁc test as it could not be used to stipulate
the involvement of peripheral or central mechanisms in
the MEMC antinociception [28]. Furthermore, this model
also has been considered to have poor speciﬁcity because
certain drugs, such as muscle relaxants, and can also reduce
the number of abdominal constriction [29]. Thus, further
studies using other nociceptive models are required before
a ﬁnal conclusion on the mechanisms of antinociception of
MEMC or other antinociceptive agents could be made.
In an attempt to determine whether the MEMC atten-
uated either the peripheral or central, or both levels of
nociception, the thermal-induced nociceptive model (e.g.,
hot plate test) was performed. This model of nociception,
which is predominantly a spinal reﬂex, is thought to involve
supraspinal nociceptive processing and to be selective for
centrally (opioids), but not peripherally (NSAIDs), acting
analgesic compounds [8, 29–31]. According to Katzung [32],
centrally acting drugs activate the release of endogenous
peptide via the periaqueductal gray matter (PAG), which
is then carried to the spinal cord to inhibit the pain
impulse transmission within the dorsal horn. Based on the
ability of highest dose of MEMC to prolong the latency
to feeling discomfort, we suggest that the extract possessed
mild centrally mediated antinociceptive activity against the
thermal-inducednociception.Themildactivitycouldbedue
to fact that the MEMC is a crude extract, which contained
various types of bioactive phytochemicals, compared to
morphine.
Another model of nociception that has been widely used
to further support the antinociceptive eﬀect observed in
any new compounds is the formalin-induced paw licking
test or formalin test [33]. Formalin injection into the
rat’s paw causes an immediate and intense increase in the
spontaneous activity of C ﬁber aﬀerent and evokes a distinct
quantiﬁable behavior indicative of pain (i.e., licking of the
injected paw) [34]. This test, which represents a model of
persistent pain, can also be used to determine the ability ofEvidence-Based Complementary and Alternative Medicine 7
new compounds to aﬀect peripheral or central nociceptive
pathways due to its biphasic nociceptive characteristics,
known as the early phase and late phase, resulting from the
formalin administration [35]. The early phase, classiﬁed as a
neurogenic pain, is an acute response observed immediately
after the administration of formalin and persists for 5min
(0–5min) as a result of a direct action of injected formalin
on nociceptors. The late phase, classiﬁed as an inﬂammatory
pain, is a tonic response resulting from the inﬂammatory
processesgeneratedbythereleaseofinﬂammatorymediators
such as histamine, serotonin, PGE and bradykinin [36],
and activation of the neurons in the dorsal horns of the
spinal cord [37, 38]. The late phase appears between 15 and
60min (15–60min) after the formalin administration. Based
on the biphasic phases, the formalin test can also be used
to determine the ability of new compounds to aﬀect the
noninﬂammatory (early phase) or inﬂammatory (late phase)
associated nociceptive response. Centrally acting drugs (e.g.,
opioids) inhibit both phases, while peripherally acting drugs
(e.g., NSAIDs) inhibit only the late phase. Based on the
results obtained, the MEMC inhibited both phases of the
formalin-induced nociception suggesting its ability to act at
central nociceptive level, which is the characteristic of mor-
phine. This ﬁnding further conﬁrms the MEMC centrally
mediated antinociceptive characteristic observed using the
hot plate test. Moreover, ability to attenuate the late phase
implies that the extract possesses not only antinociceptive,
but also anti-inﬂammatory activity [8]. Overall, results from
the three assays suggested that MEMC contains bioactive
compound(s) with central and peripheral antinociceptive
actions and additional anti-inﬂammatory activity.
Other than the role of opioid receptors, which has
been proven and discussed earlier, further studies were
also carried out to study the eﬀect of MEMC against
vanilloid receptors induced nociceptive transmission and to
explore the role of glutamatergic system and NO/cGMP
pathway in the modulation of MEMC antinociception. In
an attempt to study the eﬀect of MEMC against nociceptive
transmission via vanilloid receptors, the extract was assayed
against capsaicin-induced paw licking test. Capsaicin, an
active ingredient in hot chili peppers, directly stimulates
vanilloid receptor 1 or transient receptor potential cation
channel subfamily V member 1 (TRPV1) [39]. This types
of receptors, which are involved in the transmission and
modulation of nociceptive activity, as well as the integration
of diverse painful stimuli, selectively acting on unmyelinated
C-ﬁbers and thinly myelinated A primary sensory neurones
within the peripheral nervous system (PNS), as well as
tissues within the central nervous system (CNS) [40–43].
Interestingly, antagonists of TRPV1 receptors have been
reported to exhibit a pain-relieving activity [44]a n dw e r e
eﬀective in reducing nociception from inﬂammatory as
well as neuropathic pain models in rats [45]. Based on
our ﬁnding, the oral administration of MEMC produced a
neurogenicinhibition againstcapsaicin-inducednociception
in a dose-dependent manner indicating the ability of MEMC
to inhibit nociceptive transmission initiated by TRPV1
activation. As the TRPV1 receptors are also triggered by heat
and could be involved in the thermal-induced nociception
(e.g.,hotplatetest)[46],thepresentﬁndingsseemtosuggest
the potential of MEMC as an antagonist of TRPV1 receptors
at the peripheral and central levels.
Inanotherattempttodeterminetheroleofglutamatergic
system in the modulation of MEMC antinociception, the
extract was subjected to the glutamate-induced paw licking
test. Glutamate is a major excitatory neurotransmitter in
the CNS [47], and various reports have shown that the
glutamate and glutamatergic receptors (both ionotropic
and metabotropic glutamate receptors) are important in
the peripheral, spinal, and supraspinal nociceptive neuro-
transmission [48–50], which is greatly mediated by both
N-methyl-D-aspartate (NMDA) and non-NMDA receptors,
as well as by the release of NO and NO-related substances
[51]. On the other hand, NMDA receptor antagonists have
been proven to inhibit the spread of pain sensation and to
reduce the hyperexcitability of spinal cord neurons triggered
by C-ﬁber stimulation [52, 53]. In addition, activation of
glutamate receptors also have been reported to contribute
to the maintenance of peripheral nociceptive processes that
are associated with inﬂammatory, but not physiological pain
[54], which is concurrent with report that administration of
glutamate receptor antagonist inhibited the inﬂammatory,
but not neurogenic phases of the formalin test [55]. Based
on our ﬁndings, glutamatergic system did involve in the
modulation of MEMC antinociception.
In an attempt to determine the role of L-arginine/
NO/cGMP pathway in mediating the MEMC antinocicep-
tion, the extract’s antinociceptive activity was prechallenged
with L-arginine (a NO donor), L-NAME (an inhibitor of
NOS), and MB (an inhibitor of cGMP pathway) followed
by subjection to the abdominal constriction test. NO is
a biological molecule found inside and between cells that
reactively acts as a mediator to convey biochemical signals
resulting in a wide spectrum of eﬀects on diﬀerent biological
systems,including the CNS [56]an dPN S[57]. The resultsof
NO production are stimulation of soluble guanylate cyclase
(sGC) and rise in the cGMP level within the target cells
[57] .N Oh a sb e e nr e p o r t e dt om o d u l a t ep a i nm e c h a n i s m
a tb o t ht h eP N Sa n dC N Sl e v e l s[ 58] with the high level
of NO induces pain and vice versa [59]. Other than that,
NO has been implicated as a mediator or modulator in
analgesic drug function [60]. In line with those reports,
the peripheral activation of the NO-cGMP pathway has
been implicated in various nociceptive conditions [61]. The
diﬀerential eﬀect that NO has might be due to the fact
that each tissue might be or is predominantly innervated
by diﬀerent subsets of primary nociceptive neurons [62].
Based on our ﬁndings, increase in NO level reversed the
MEMC antinociception while reduction in NO level did
not aﬀect the extract antinociception. This observation is
concurrent with suggestion that the eﬀect of NO depends
on dosage levels and the rate and timing of its release
[58, 59]. In addition, failure of L-NAME to enhance but
instead maintain MEMC antinociception is suggested to be
due to the amount of NO inhibited within the peripheral
level was enough to prevent activation of various nociceptive
pathways associated with NO (i.e., COX, glutamatergic, or
TRPV1 systems). Furthermore, based on our observation, it8 Evidence-Based Complementary and Alternative Medicine
is suggested that the inhibition of cGMP pathway, whether in
the presence or absence of NO, will lead to antinociception
and, in the presence of MEMC/other antinociceptive agents,
will enhance the agents antinociceptive eﬀect. MB has
been widely applied in researches involving pain perception
because it has been shown to act as a less speciﬁc and potent
guanyl cyclase (GC) inhibitor, which directly blocked NOS
and decreased the accumulation of cGMP. GC is one of the
main targets of NO [63], thus, MB is frequently used to
clarifytheinvolvementofcGMPpathwayintheeﬀectsofNO
system on mechanisms of pain. The ability of MB to enhance
MEMC antinociceptive activity corroborates with previous
reports [59, 61–63]. Thus, the present ﬁndings supported
the involvement of NO/cGMP pathway in the modulation of
peripheral antinociception of MEMC.
We have recently reported the presence of ﬂavonoids,
tannins, and saponins in the MEMC [11]. Flavonoids could
be responsible for the observed antinociceptive activity of
MEMC as this class of compounds has been reported to
modulate pro-inﬂammatory gene expression like inducible
NOS and COX-2 [64]. Thus, the ability of ﬂavonoids to
modulate various pain pathways could be used to explain on
the recent observations.
5. Conclusion
The present study demonstrated that the MEMC possessed
both central and peripheral antinociceptive activities that
involve inhibition of COX activity or PGE synthesis as well
asactivationofopioid, glutamatergicsystem,andNO/cGMP
pathway. The MEMC also exhibited inhibitory eﬀect against
TRPV1-receptor-mediated nociceptive transmission. These
activities are attributed to the possibly synergistic action of
ﬂavonoids, saponins, and tannins present in the extract. Fur-
ther studies are now in progress to determine the bioactive
compound(s) responsible for the analgesic properties of M.
calabura.
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